Back to search results

Observational Study for T-Cell and NK-Cell Neoplasms

This is an observational study for people with T-cell and NK-cell neoplasms (a type of blood cancer). Researchers want to understand how changes in your genes relate to how well treatments work and how long you live. They will collect information about your health, tumor, and treatments for up to four years. The goal is to use this information to find better, more personalized treatments in the future. You may be able to join if you are 18 or older and have a newly diagnosed, relapsed, or difficult-to-treat T-cell or NK-cell neoplasm. Certain types of T-cell and NK-cell cancers are not included. The study will look at how long people live overall, how long they live without their cancer getting worse, and how long their treatment response lasts.

Study design
This is a prospective, longitudinal observational study involving about 1200 participants globally. It is not testing a specific drug, but rather observing patients' journeys.
What's involved
You will be enrolled during your first visit as a new patient and followed for up to four years. Researchers will collect routine information about your health, tumor, treatments, and quality of life.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to four years after enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06067347

A Global Study of the PETAL Consortium

Recruiting
Not specifiedAges 18+Observational
Massachusetts General Hospital
~1,200 participants
Updated 2026-04-09 on ClinicalTrials.gov

At a glance

Recruiting sites
14 of 14 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall Survival
Measured over Up to 4 Years
+5 more outcomes measured

Conditions

T-Cell and NK-Cell Neoplasm

Explore related trials

T-Cell and NK-Cell Neoplasm

NCT06067347

Where you'd take part

This study runs at 14 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • City of Hope

    Duarte, Californiastudy coordinator listed

    Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusettsstudy coordinator listed

    Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jerseystudy coordinator listed

    Recruiting

  • Kyoto University

    Kyoto, Japanstudy coordinator listed

    Recruiting

  • Massachusetts General Hospital

    Boston, Massachusettsstudy coordinator listed

    Recruiting

  • Mayo Clinic

    Rochester, Minnesotastudy coordinator listed

    Recruiting

  • Moffitt Cancer Center

    Tampa, Floridastudy coordinator listed

    Recruiting

  • OhioHealth

    Columbus, Ohiostudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Salvia Jain, MD
[email protected]
650-224-0183
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Untreated, relapsed, or refractory histologically confirmed mature T-cell or NK-cell neoplasm.
All subtypes of PTCL are eligible except for T-cell large granular lymphocytic leukemia, cutaneous T-cell lymphoma such as but not limited to mycosis fungoides and transformation, Sézary syndrome, and primary cutaneous CD30+ disorders.

Exclusion

Precursor T/NK neoplasms, T-cell large granular lymphocytic leukemia, cutaneous T-cell lymphoma such as but not limited to mycosis fungoides and transformation, Sézary syndrome, and primary cutaneous CD30+ disorders.
Adults who are unable to consent, individuals who are not yet adults such as infants, children and teenagers, pregnant women, and prisoners.

What this trial measures

  • Overall SurvivalUp to 4 Years

    Difference in overall survival (OS) in subjects with primary refractory versus relapsed mature T-cell and NK-cell neoplasms at the completion of 4 years.

  • Progression-free SurvivalUp to 4 Years

    Difference in progression-free survival (PFS) in subjects with primary refractory versus relapsed mature T-cell and NK-cell neoplasms at the completion of 4 years.

  • Duration of ResponseUp to 4 Years

    Difference in duration of response in subjects with mature T-cell and NK-cell neoplasms treated with cytotoxic chemotherapy versus prespecified non-chemotherapeutic choice at the completion of 4 years.

  • Time to progressionUp to 4 Years

    Difference in time to progression in subjects with mature T-cell and NK-cell neoplasms treated with cytotoxic chemotherapy versus prespecified non-chemotherapeutic choice at the completion of 4 years.

  • Number of subjects proceeding to stem cell transplantationUp to 4 Years

    Difference in number of subjects bridged to stem cell transplantation (allogeneic or autologous) with mature T-cell and NK-cell neoplasms treated with cytotoxic chemotherapy versus prespecified non-chemotherapeutic choice at the completion of 4 years.

  • Association of tumor specific somatic variants with treatment responseUp to 4 Years

    Determine whether tumor specific somatic variants identified at the time of diagnosis predicts response to treatment in subjects with mature T-cell and NK-cell neoplasms at the completion of 4 years in at least 50% of the patients.